Pharmaceutical composition for preventing and treating intestinal colibacillosis of yak calves and preparation method of pharmaceutical composition

A technology for colibacillosis and a composition, which is applied in the field of veterinary medicine, can solve problems such as drug resistance of pathogenic Escherichia coli, public health threats, and drug residues in feces, and achieves the advantages of protecting biological activity, reducing the number of Escherichia coli, and being convenient to take. Effect

Pending Publication Date: 2021-11-05
LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the main means of preventing and treating the disease is still based on antibiotics, and the selective pressure caused by antibiotics on bacteria is the most important factor in inducing and accelerating drug resistance, which leads to the emergence of drug resistance in pathogenic Escherichia coli. Larger and bigger, poor efficacy
In addition, the problem of drug residues in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing and treating intestinal colibacillosis of yak calves and preparation method of pharmaceutical composition
  • Pharmaceutical composition for preventing and treating intestinal colibacillosis of yak calves and preparation method of pharmaceutical composition
  • Pharmaceutical composition for preventing and treating intestinal colibacillosis of yak calves and preparation method of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The preparation method of embodiment 1 pharmaceutical composition, the steps are as follows:

[0020] Materials: Artemisinin (CAS63968-64-9, Lot#C10420277, ≧98%), purchased from Shanghai Macklin Biochemical Technology Co., Ltd.; Sodium Selenite Tablets (1.0mg / tablet, National Drug Approval H37023197, Lot No. 20190845) , purchased from Shandong Xili Pharmaceutical Co., Ltd.; ferrous sulfate (analytical pure AR, CAS7782-63-0, batch number 20190722), purchased from Sinopharm Chemical Reagent Co., Ltd.; shell powder (food grade, 600 mesh, batch number 20190516) , purchased from Hebei Huihao Environmental Protection Technology Co., Ltd.; mannan oligosaccharide (food grade, purity 99%, product number 15516382283), purchased from Zhengzhou Best Food Additive Co., Ltd.; antibiotic norfloxacin (NOR, CAS70458-96- 7. Lot#N814880, ≧98%), purchased from Shanghai Macklin Biochemical Technology Co., Ltd.; Ampicillin Sodium (AMP, Lot. No. 826H031, ≧85%), purchased from Beijing Suo Laib...

Embodiment 2 4

[0047] The drug susceptibility of embodiment 2 four strains of escherichia coli and the drug-resistant bacterial spectrum determination (K-B method)

[0048] Follow the steps recommended by the National Committee for Clinical Laboratory Standards (NCCLS). Test strain: Escherichia coli (E.coli, ETEC-O 78 K 80 , CICC10421), Escherichia coli (E.coli, CICC10302), purchased from China Industrial Microorganism Culture Collection Management Center; Escherichia coli (E.coli, BNCC125787), Escherichia coli (E.coli, BNCC186347) , purchased from Beijing Beina Chuanglian Biotechnology Research Institute.

[0049] (1) A single colony of Escherichia coli freshly cultivated was prepared with 0.45% sterile physiological saline solution to prepare a suspension of the tested bacteria at a concentration equivalent to 0.5 McFarland. Spread it evenly on the surface of MH nutrient agar to prepare an MH agar plate containing bacteria to be tested.

[0050] (2) Paste the drug-sensitive paper sheet...

Embodiment 3

[0056] Example 3 Study on the combined antibacterial and sensitizing effect of artemisinin and 2 kinds of antibiotics

[0057] (1) Determination of MIC values ​​of artemisinin and 2 kinds of antibiotics against 4 strains of pathogenic Enterobacteriaceae (96-well plate micro broth dilution method and E-test)

[0058] Follow the microdilution steps recommended by the National Committee for Clinical Laboratory Standards (NCCLS). Pipette the MH broth into the NEST 96-well plate, 100 μL per well. Add 100 μL of the drug solution to the first well of the above-mentioned NEST 96-well plate containing MH broth, blow and mix with an exhaust gun, and then dilute to the 11th hole sequentially by the doubling dilution method, and the 12th hole does not add the drug as a positive control. Add 100 μL of the prepared bacterial solution to each well of the 1st to 10th and 12th columns of the NEST 96-well plate, and no bacteria were added to the 11th well as a negative control. Add bacterial ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for preventing and treating intestinal escherichia coli infection of yak calves. The pharmaceutical composition is prepared from the following components: artemisinin, antibiotics, trace element selenium, ferrous sulfate, shell powder and mannan oligosaccharide. The invention further provides a preparation method of the pharmaceutical composition and application of the pharmaceutical composition in preventing and treating intestinal colibacillosis of yak calves. The pharmaceutical composition can be used for improving the drug sensitivity of drug-resistant escherichia coli and the antibacterial effect of fluoroquinolone-or beta-lactam antibiotics and can be used for treating hemorrhagic diarrhea of yak calves caused by enterotoxigenic escherichia coli infection, and the prepared dosage form is convenient for clinical use; and meanwhile, the pharmaceutical composition can further promote the body immune function and production performance of the yak calves, enhance the resistance of the yak calves to pathogenic bacteria escherichia coli and improve the immunity of yak groups. According to the preparation method, material selection is convenient, cost is relatively low, and large-scale production is easy to form.

Description

technical field [0001] The invention relates to the technical field of veterinary medicine, in particular to a pharmaceutical composition for preventing and treating calf colibacillosis and a preparation method thereof. Background technique [0002] The number of yaks stocked in China accounts for about 90% of the total number of yaks in the world, and they are mainly distributed in high-altitude and high-altitude areas. Since ancient times, yaks have been the dominant domestic animal in my country's plateau areas and an important source of income for herdsmen. Calf enteric colibacillosis is an important infectious disease of newborn yaks, mainly through the digestive tract, and may also be infected through the uterus and umbilical cord. The disease can occur throughout the year, and occurs frequently in the calving season in spring. It is common in calving yaks within 20 days of age and is endemic. Any factor that can reduce the resistance of calving yaks can induce and pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/618A61P31/04A61P37/04A61K31/366A61K31/43A61K31/496A61K31/702A61K33/04A61K33/26
CPCA61K31/366A61K33/04A61K33/26A61K35/618A61K31/702A61K31/496A61K31/43A61P31/04A61P37/04A61K2300/00Y02A50/30
Inventor 王玲郭文柱沙赫巴兹郭志廷崔东安王淑芳杨峰魏小娟王春梅付鹏程杨珍程峰吕嘉文
Owner LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap